Industry, patient groups weigh in on Trump's drug pricing plan

The drug industry’s main lobbying arm has proposed limiting how much drug middlemen can pocket for selling medicines, a position it is calling a “bold new stance.”

The middlemen, known as pharmacy benefit managers, have taken heat from the Trump administration for their purported role in high prices that patients pay for medications. Pharmacy benefit managers negotiate drug prices for health insurance companies, but have been accused of not passing on savings from rebates to patients.